April 27, 2020 / 12:45 AM / a month ago

BRIEF-Hua Medicine Announces Positive Results Of Combination Study Of Dorzagliatin With Empagliflozin (A Sglt-2 Inhibitor)

April 27 (Reuters) - Hua Medicine:

* ANNOUNCES POSITIVE RESULTS OF COMBINATION STUDY OF DORZAGLIATIN WITH EMPAGLIFLOZIN (A SGLT-2 INHIBITOR)

* CLINICAL STUDY IS PHASE I TRIAL CONDUCTED IN U.S. IN TYPE 2 DIABETES (T2D) PATIENTS WITH INSUFFICIENTLY CONTROLLED BLOOD GLUCOSE LEVELS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below